Status:
COMPLETED
Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Painful Diabetic Peripheral Neuropathy
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study is to test the effectiveness of pregabalin in treating nerve pain caused by diabetes. The suitable subjects will be patients who also use an non-steroid anti-inflammatory drug for another p...
Eligibility Criteria
Inclusion
- Type 1 or 2 diabetes with painful neuropathy
- Currently treated with one NSAID (including COX 2 inhibitors) for a co morbid pain condition with a regular dose
- Meet pre-defined level of pain severity at entrance
Exclusion
- History of failed pregabalin treatment due to lack of efficacy at therapeutic dose
- Participated in a previous or ongoing pregabalin clinical trial
- Neurologic disorders unrelated to diabetic neuropathy that may confound the assessment of distal neuropathic pain
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
306 Patients enrolled
Trial Details
Trial ID
NCT01455415
Start Date
December 1 2011
End Date
December 1 2013
Last Update
January 28 2021
Active Locations (61)
Enter a location and click search to find clinical trials sorted by distance.
1
Dedicated Clinical Research
Goodyear, Arizona, United States, 85395
2
Clinical Research Consortium
Phoenix, Arizona, United States, 85004
3
Arizona Research Center
Phoenix, Arizona, United States, 85023
4
Advanced Podiatry
Phoenix, Arizona, United States, 85032